Thymosin beta-4: adverse events in a trial
The abstract of a synthetic thymosin beta-4 trial describes 40 healthy volunteers, intravenous exposure and a repeated 14-day course. Adverse events were infrequent and mild or moderate; no serious events or dose-limiting toxicity were reported. [1]
The abstract gives no event-specific frequencies. This short intravenous trial does not establish lasting risks or safety of a particular reagent batch, the TB-500 fragment or blends. [1]
What the studies reported
| Effect | Model or participants | How often or as described | Source |
|---|---|---|---|
| Adverse events overall | 40 healthy volunteers, intravenous synthetic thymosin beta-4, single dose and a repeated 14-day course | Were infrequent and mild or moderate; the abstract gives no event-specific frequencies | [1] |
| Serious events and dose-limiting toxicity | The same volunteers | None reported | [1] |